预测自身免疫病CAR-T治疗后细胞因子释放综合征
[Comment] Predicting cytokine release syndrome after CAR T-cell therapy for autoimmune diseases
RSS 订阅 · Lancet Rheumatology
本文指出CAR-T治疗知识多源于肿瘤领域,不能简单外推至自身免疫病。
要点
- CAR-T治疗自身免疫病时CRS通常较轻,与肿瘤领域经验不同。
- 肿瘤领域的CAR-T毒性预测不能直接外推至自身免疫病。
核心结论
- CAR-T治疗自身免疫病时CRS通常较轻,肿瘤领域经验不能简单外推。
局限性
- 多数CAR-T知识源于肿瘤领域,仅部分可转移至自身免疫病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most of what is known about chimeric antigen receptor (CAR) T-cell treatment is derived from oncology, and only part of it transfers to autoimmune diseases. In autoimmune diseases, CAR T-cell persistence and toxicity can differ; oncological experience cannot simply be extrapolated. Cytokine release syndrome (CRS), the systemic inflammatory reaction that often follows treatment with CAR T cells, is the most common toxic effect, and in autoimmune diseases it is usually mild: in one of the first published case series, ten of 15 patients had grade 1 CRS and one had grade 2 CRS.
来源:Lancet Rheumatology,查看原文。版权归原作者所有。
引用
- Lancet Rheumatology:[Comment] Predicting cytokine release syndrome after CAR T-cell therapy for autoimmune diseases
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。